Assessment of Magnesium administration effect on Atrial Fibrillation duration in patients admitted to the Intensive Care Unit.

Phase 4

Recruiting

• Conditions: Atrial Fibrillation; Cardiovascular - Other cardiovascular diseases; Emergency medicine - Other emergency care

• Registration Number: ACTRN12622001076763
• Lead Sponsor: Prof Rinaldo Bellomo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-04
• Last Update Posted: 27 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Patients who are invasively mechanically ventilated and receiving vasoactive agents.

Exclusion Criteria

1. Patients who are allergic to the allocated trial drug.
2. Patients who have undergone cardiac surgery.
3. Pre-eclampsia, eclampsia, or post-partum hypertension.
4. Patients who are known to have atrial fibrillation.
5. Patients with severe Chronic Kidney Disease (eGFR<30ml/min).
6. Patients who Have severe oliguria (<0.5 ml/kg/hr for 12 hours)
7. Patients with serum total Magnesium level of < 0.4mmol/l.

Study & Design

• Study Type: Interventional
• Study Design: Not specified